Kurischko et al., http://www.jcb.org/cgi/content/full/jcb.201011061/DC1




Figure S1. Physiologically expressed Ssd1 colocalizes with P-bodies in glucose-depleted cells. (A) Cells expressing Ssd1-GFP under control of its physiological promoter and RFP-tagged P-body and stress granule proteins were transferred to glucose-depleted medium for 10 min and analyzed by spinning disk confocal microscopy. The RFP-tagged proteins (Edc3, Lsm1, Dcp2, and Pub1) were encoded by plasmids (see Table II). Most (~90%), but not all Ssd1 puncta colocalize with P-body and stress granule proteins. All images represent single optical sections. Bars, 2 μm. (B) Ssd1 immunoblot showing comparative analysis of Ssd1 expression from GPD promoter vs. endogenous promoter. Cells expressing integrated Ssd1-GFP and plasmid-borne GPD promoter-driven Ssd1-GFP (FLY1593 and FLY2184 + FLE1019) were TCA precipitated and processed for immunoblots as described in Materials and methods. Based on immunoblot analysis, GPD-driven Ssd1 (on low copy plasmid) is expressed approximately sevenfold higher than physiologically expressed Ssd1.




Figure S2. *UTH1* is a dosage suppressor of *cbk1-8* mutants. Serial dilution of conditional *cbk1-8* mutant cells (FLY2884) containing empty vector, *CBK1*, and high copy *UTH1* plasmid (pGP564, FLE1171, pGP564-UTH1).




Figure S3. Ssd1 precipitates SRL1, SIM1, CCW12, SUN4, DSE2, SCW4, and CT51 mRNAs and does not affect steady-state mRNA levels. (A) Strain FLY2184 was transformed with either pGPD-SSD1-GFP (FLE1019; lane 1 for each gene) or pGPD-SSD1 $^{1.520}$ -GFP, which lacks the RNA-binding domain (FLE1020; lane 2). Lane 3 represents the untransformed strain. Ssd1-GFP was immunoprecipitated with an anti-GFP monoclonal antibody. The presence of the precipitated mRNAs was shown by RT-PCR. (B) Steady-state levels of SRL1, CCW12, and SIM1 mRNA in SSD1 and $ssd1\Delta$ cells are indistinguishable. Quantitative RT-PCR was performed as described in Materials and methods. The relative levels of query mRNA transcripts were compared with that of ACT1 mRNA (top) and ADH1 mRNA (bottom).






Figure S4. **Ssd1-9A, but not Ssd1-9A-RBD\Delta** expression causes **SRL1 mRNA to localize to P-bodies.** (A) Cells expressing GAL-inducible Ssd1-9A-HA and *SRL1* mRNA-GFP (FLY3196 with plasmid FLE1208) were transferred to galactose medium for 1–2 h and *SRL1* mRNA localization was observed by widefield fluorescence microscopy. (B) Representative images of SRL1 mRNA distribution in $ssd1\Delta$ cells expressing GPD promoter-driven Ssd1-9A-RBD Δ (FLE1278). The distribution of SRL1 mRNA localization in Ssd1-9A-RBD Δ cells is: no mRNA spots 15.6%, M 15.9%, D 25.3%, M+D 29.6%, multiple faint spots 13.6% (n = 257 cells). All images represent single optical sections. Bars, 2 μ m.





*B+: same as B, but treated with RNAse

Figure S5. Confirmation of SRL1 mRNA tag expression in wild-type and $ssd1\Delta$ cells. SRL1 mRNA was tagged as described in Haim et al. (2007). The sequential steps are shown: (A) Integration of the MS2-CP-GFP cassette; (B) Loop-out of the selective marker; (C) SRL1 locus without integration of the cassette. Each step was monitored by RT-PCR and reveals different sizes of the PCR products. There is no detectable difference in the expression of SRL1 mRNA in SSD1 and $ssd1\Delta$ strains.

Reference

Haim, L., G. Zipor, S. Aronov, and J.E. Gerst. 2007. A genomic integration method to visualize localization of endogenous mRNAs in living yeast. *Nat. Methods*. 4:409–412.